The human transforming growth factor-alpha (TGF-a) gene is thought to contain ®ve introns and six exons, encoding a transmembrane precursor (proTGF-a) from which the mature polypeptide is released by proteolytic cleavage. We identi®ed a novel 32-nucleotide exon (exon a) within intron 5 and an alternative splice acceptor site in exon 6, splitting exon 6 into two segments: 6A and 6B. Therefore, in addition to wild type (wt) proTGF-a mRNA, which skips exon a, two novel proTGF-a variants are produced: Variant I (VaI), skipping exons a and 6A, and Variant II (VaII) which includes exon a and skips exon 6A. The only signi®cant dierence between variant and wt proTGF-a proteins is that the two wt carboxyl-terminal valines are replaced in the variants by ®ve or four other amino acids, respectively. Both variant TGF-a mRNAs were readily detected in human keratinocytes and tumor-derived cell lines. Their protein products were cleaved as eciently as wt TGF-a in response to the calcium ionophore A23187. However, both variants (but not wt) reduced serum requirements for proliferation in CHO cells. In addition, VaIIexpressing CHO cells (not VaI or wt) formed foci in monolayer cultures. These results suggest that variant TGF-a precursors induce autonomous growth.
Introduction
The human transforming growth factor-a (TGF-a) gene, localized to chromosome 2p13, spans about 100 kb, and contains 6 exons and 5 introns (Derynck et al., 1985; Lee et al., 1995) . The 4.4-kb TGF-a mRNA encodes a 160-amino acid transmembrane precursor (proTGF-a). Mature TGF-a is a 50-amino acid single polypeptide derived from proTGF-a by two independent proteolytic cleavages (Massague and Pandiella, 1993; Lee et al., 1995) . The cleavage enzyme(s), which exhibits an elastase-like speci®city, has yet to be identi®ed. The ®rst cleavage between Ala 39 and Val 40 is rapid and not tightly regulated. The second cleavage between Ala 89 and Val 90 is slow and highly regulated. TGF-a cleavage is induced by various signals, including protein kinase C activation, rise of intracellular calcium, EGF receptor signaling, and serum factors (Lee et al., 1995) . The cytoplasmic domain of proTGF-a is only 39 amino acids and contains two carboxyl-terminal valine residues. These valine residues were thought to be critical for complete processing and release of mature TGF-a in transfected CHO cells (Bosenberg et al., 1992) . However, more recently it was demonstrated that the carboxyl-terminal valine residues of proTGF-a are required for its ecient maturation, rather than for proteolytic processing (Briley et al., 1997) . The cytoplasmic region is highly conserved among dierent species, and does not contain any obvious enzymatic motifs (Shum et al., 1996) .
A large variety of cells, primarily of ectodermal origin, synthesize TGF-a and skin is a major source of TGF-a (Wilcox and Derynck, 1988) . Many tumor cell types, especially carcinomas, overexpress TGF-a in comparison with normal cells (Derynck et al, 1987) . TGF-a was characterized as a target for the von Hippel-Lindau (VHL) tumor suppressor gene that has a critical role in the pathogenesis of clear cell renal carcinoma. VHL acts by decreasing TGF-a mRNA stability (Knebelmann et al., 1998) . In several human tumor-derived cell lines that express endogenous TGFa and EGF receptor, membrane-bound proTGF-a represents a signi®cant portion of the total TGF-a expressed (Brachmann et al., 1989; Ezzat et al., 1995; Baselga et al., 1996; Seki et al., 1997) .
We have previously observed, in our in vitro model of HPV16-mediated human cell carcinogenesis (Pirisi et al., 1987 (Pirisi et al., , 1988 Zyzak, et al., 1994; DiPaolo et al., 1989 DiPaolo et al., , 1990 ) that human keratinocytes immortalized with human papillomavirus type 16 DNA (HKc/ HPV16) secrete 50 ± 100-fold less mature TGF-a than normal human keratinocytes (HKc), despite the fact that mRNA levels for TGF-a are either unchanged or slightly increased (Zyzak et al., 1994) . These results may indicate that HPV16-transformed cells have lost the enzyme activity required for TGF-a processing, or that the cells express isoforms of proTGF-a that are incompletely processed. The nucleotide sequence encoding the carboxyl-terminal valine residues of proTGF-a (G;TG GTC TGA), shown to be necessary for maturation and correct tracking of the precursor, spans the splice junction of exon 5 and exon 6 of the TGF-a gene. This sequence is followed, in exon 6, by the stop codon and a 3' untranslated region (UTR) of about 3.5 kb (Derynck et al., 1985) . We reasoned that alternative splicing at the junction of exons 5 and 6 might result in the replacement of the two carboxyl-terminal valine residues thought to be critical for maturation and processing of proTGF-a. Therefore, we set out to determine whether alternatively spliced forms of TGF-a mRNA could be identi®ed in normal HKc and HKc/HPV16. This work resulted in the identi®cation of a novel 32-nucleotide exon within intron 5 and a new splice acceptor site within exon 6 of the TGF-a gene. Thus, in addition to wt proTGF-a, alternative splicing of the TGF-a precursor mRNA generates two proTGF-a variants, which we have named here variant I (VaI) and variant II (VaII). The two variants are dierent from wt proTGF-a in that ®ve or four other amino acids in the variants replace the two carboxyl-terminal valine residues in the wt. Both variant mRNAs were readily detected in normal HKc, HKc/HPV16, and a variety of human tumor-derived cell lines. Both variant TGF-a precursors overexpressed in CHO cells were as susceptible to calcium ionophore-induced cleavage as wt TGF-a. However, CHO cells expressing VaII were morphologically dierent from those expressing wt TGF-a or VaI, and formed foci when con¯uent in monolayer cultures, while CHO cells expressing either wt TGF-a or VaI did not. In addition, CHO cells expressing variant TGF-a precursors grew signi®cantly better than those expressing wt TGF-a in medium with reduced serum, suggesting that the TGF-a variants are capable of promoting autonomous growth.
Results
Exon 6 of the human TGF-a gene consists of 3.5 kb, encoding the two carboxyl-terminal valine residues and 3' UTR. We identi®ed several potential splice acceptor sites within exon 6 that match the splice acceptor consensus sequence (Py) 10 N(C/T)AG, where Py is a pyrimidine and N is any nucleotide (Mount, 1982) . To determine whether these alternative splice acceptor sites were functional, we designed primers to amplify the region spanning from exon 5 to several possible alternative splice acceptor sites within the 3' UTR in exon 6, and used these primers in RT ± PCR reactions on the template of RNA isolated from normal HKc, HKc/HPV16 and HKc/GFI. These experiments allowed us to identify an alternative splice acceptor site at nucleotide 1751 of the TGF-a cDNA (GenBank, accession number X70340) and to demonstrate that this site was consistently used in normal HKc, HKc/ HPV16, and HKc/GFI (data not shown). The splice acceptor site at nucleotide 1751 matched the splice acceptor site consensus sequence (Mount, 1982) .
We then designed primers¯anking the translation start codon in the TGF-a mRNA and the alternative splice site at nucleotide 1751, and used these primers to amplify the full-length coding sequence of the TGF-a precursors, again by RT ± PCR on RNA from HKc. We isolated and sequenced ®ve cDNA clones, each containing full-length coding sequences for TGF-a precursors. These clones allowed us to identify three dierent transcripts: (1) In the ®rst transcript, splicing from the donor site at exon 5 continued into the alternative splice acceptor site at nucleotide 1751, within exon 6 (Figure 1a , VaI, and compare Figure  1b ,c, VaI). This 782-nucleotide transcript, which we have designated as TGF-a variant I, encodes 163 amino acid residues identical to wt proTGF-a in all but the carboxyl±terminus, in which the sequence GCRLY replaces the wt VV ( Figure 1d ); (2) In the second transcript, micro-heterogeneity splicing between intron 2 and exon 3 (due to the trinucleotide sequence repeat CAG at the end of intron 2) results in a 779-nucleotide mRNA, encoding a polypeptide identical to TGF-a variant I, except for the lack of an alanine residue in the short region between the signal peptide and the EGF-like sequence. The same micro-heterogeneity splicing event has been described in rat TGF-a, and was thought to have no eect on the function and processing of the molecule (Blasband et al., 1990; Lee et al., 1995) . This transcript was designated as TGF-a variant IM (data not shown). It is quite possible that wt TGF-a mRNA may also exist in this micro-spliced form; (3) In the third transcript, splicing from the donor site of exon 5 continued into a novel exon of 32 Table 1 ). We have designated this transcript as TGF-a variant II. TGF-a VaII encodes a protein of 161 amino acids in which the carboxyl-terminal sequence ATLG replaces the two valine residues at the carboxyl-terminus of the wt proTGF-a ( Figure 1d ). The TGF-a VaII mRNA we isolated also lacks an alanine residue in its N-terminal domain, due to microheterogeneity splicing between intron 2 and exon 3.
To con®rm the origin and authenticity of exon a, we cloned and sequenced the genomic DNA fragment encompassing exons 4, 5 and 6 of the TGF-a gene with the intervening introns, and determined that the novel 32-bp exon a is contained in intron 5, and is¯anked by canonical splice donor and splice acceptor sites (Table  1) (Mount, 1982) . The sequence we obtained for intron 5 matches a partial sequence for this region of the TGF-a gene that had been previously reported by Qian et al. (1993) (GenBank accession number X70341).
Based on the results presented above, the structure of the TGF-a gene ( Figure 1b ) was re-de®ned as follows: Exon 6 is split into two segments, 6A and 6B, de®ned by the alternative splice acceptor site at nucleotide 1751 (Figure 1b,c; Table 1 ). In addition, a new exon (exon a) was identi®ed within intron 5 ( Interestingly, both variants are characterized by the loss of the carboxyl-terminal valine residues that are thought to be critical for maturation and intracellular tracking of the transmembrane TGF-a precursor (Briley et al., 1997) (Figure 1d ). A Prosite database search (http://www.expasy.ch) identi®ed a possible prenylation site (CAAX box, where C is cysteine and A is an aliphatic amino acid) at the carboxyl-terminus of TGF-a variant I.
To con®rm that the transcripts of the two TGF-a variants were expressed, and to explore the expression levels of each variant in normal HKc, HKc/HPV16, and human tumor-derived cell lines, we designed Figure 3 Diagram of two-step PCR-based site-directed mutagenesis used to insert the HA tag into the TGF-a sequence. (a) The 5' end primer contained a Kozak sequence (striped box) upstream of the ®rst ATG, and an EcoRI site at its 5' end. The ®rst 3' primer was used to incorporate the HA tag (solid box) into the template. The product of the ®rst PCR, obtained using the 5' end primer and the ®rst 3' end primer, was then used as the forward primer for a second round of PCR, with a second 3' end primer located downstream from the stop codon of the template coding sequence. The resulting product was cloned into the pGEMTeasy vector. (b) Diagram of the resulting HA-tagged proTGF-a, showing the position of the HA tag near the N-terminus of the mature TGF-a (between amino acid positions 4 and 5). SP, signal peptide; TM, transmembrane region Figure 4 Processing of HA-tagged wt and variant TGF-a in CHO cells, in response to calcium ionophore treatment. (a) CHO cells stably transfected with HA-tagged wt TGF-a or TGF-a variants were serum-starved for 1 h, then treated with 1 mM calcium ionophore A23187 (in DMSO) for the time indicated. Control cells were maintained in serum-free medium (Ss) or in serum-free medium containing 0.1% DMSO (DMSO) for 3 h. Equivalent amounts of total cell lysate protein were separated by SDS ± PAGE and Western blot analysis performed using anti-HA antibodies. The results were visualized by chemiluminescence and exposure to X-ray ®lm. (b) Decay curve of wt (circles) and variant (squares, VaI; triangles, VaII) proTGF-a constructed based on scanning densitometric analysis of the Western blot results shown in (a) riboprobes speci®c to each variant and to wt TGF-a, and used these probes in ribonuclease protection assays (RPAs). The antisense RNA probe speci®c for wt TGF-a was designed to protect a 273 nucleotide fragment at the 3' end of exon 6A (Figure 2a ) which is not contained in either variant. Therefore there is no competition between wt and variant TGF-a mRNAs for this probe. A probe for VaI was constructed to protect a 307 nucleotide fragment encompassing the alternative splice junction between exon 5 and exon 6B (Figure 2a,b) . This probe also detects the wt TGF-a transcript in exons 5 and 6B, giving rise to two smaller protected fragments (176 bases and 131 bases respectively) (Figure 2b ). However, this probe does not interfere with binding of the wt TGF-a probe to wt TGF-a mRNA. The probe for VaII protected a 339 nucleotide fragment containing the splicing junctions between exons 5 and a, the entire exon a, and the junction between exons a and 6B (Figure 2a,c) . This probe also hybridizes with wt TGF-a mRNA and produces two smaller protected fragments (176 bases and 131 bases), however it does not compete with the wt TGF-a speci®c probe for binding to wt TGF-a mRNA. RPAs using the three speci®c probes determined that TGF-a VaI was expressed at levels approximately 50 ± 100% of wt TGF-a, while TGF-a VaII mRNA levels were much lower, in normal HKc, HKc/HPV16, HKc/GFI, and HKc/DR (Figure 2d) . No dramatic changes in either the levels of total TGFa mRNA expressed or the ratios between variant and wt TGF-a mRNA levels were observed in HKc/ HPV16, in comparison with their normal HKc strains of origin (compare normal HKc strain Z6P1 with HKc/HPV16 lines Z6P3, -P4, and -P7 in Figure 2d) . The TGF-a variants were also expressed in most of the human tumor-derived cell lines we examined (13 cell lines in total). Surprisingly, the levels of wt TGF-a transcript ranged from low to almost undetectable in C33A, SiHa, HeLa, HT69, MG63, Saos-2, Detroit 562, and SW 837 (Figure 2e and data not shown). However, all of these cell lines retained expression of both variant TGF-a mRNA species (Figure 2e and data not shown).
We then asked whether the TGF-a variants were processed to release soluble TGF-a. We incorporated the in¯uenza HA epitope between amino acids 42 and 43 which correspond to position 4 (His) and 5 (Phe) of the fully processed 50-amino acid mature TGF-a, using a two-step PCR-based site-directed mutagenesis procedure (Figure 3 , and Materials and methods). This region of the mature TGF-a is thought to be relatively unimportant for its function, and it has been previously shown that the HA tag at this position does not aect processing of the TGF-a precursor (Briley et al., 1997) . HA-tagged wt and variant TGF-a cDNAs were cloned into the expression vector pcDNA3.1 (Invitrogen) and stably expressed in CHO K1 cells. Individual clones were selected which expressed high levels of the TGF-a forms as determined by RPAs and Western blot analysis with anti-HA antibody. Previous studies have demonstrated that proteolytic cleavage of the TGF-a precursor can be stimulated by PMA, calcium ionophore, and serum (Massague and Pandiella, 1993) . We explored TGF-a cleavage in the CHO cells expressing HA-tagged wt and variant TGF-a, by Western blot analysis with anti-HA antibodies, in cell lysates harvested after treatment with or without serum or the calcium ionophore A23187. Both TGF-a variants were as susceptible to calcium ionophore A23187-induced cleavage as wt TGF-a (Figure 4) . Serum also induced cleavage of all three TGF-a forms, although less eciently than A23187 (not shown).
We observed that CHO cells overexpressing TGF-a VaII were morphologically dierent from vectortransfected CHO cells, being more elongated and spindle-shaped (Figure 5a ). In addition, these cells have the capacity to form foci at con¯uence (an average of 10 foci/100-mm dish), while mocktransfected CHO cells and CHO cells overexpressing wt TGF-a precursor or VaI do not form foci (a representative focus from CHO/VaII cells is shown in Figure 5a ). We isolated a subline from a focus of CHO cells overexpressing TGF-a VaII and determined, by Western blot analysis with anti-HA antibodies, that this focus-derived subline expressed at least tenfold higher TGF-a VaII protein than the original population (Figure 5b) suggesting that overexpression of VaII may result in a growth advantage for these cells. We then conducted clonal growth and mass culture growth assays to determine whether overexpression of wt TGF-a or the variants in CHO cells resulted in 
Discussion
The human TGF-a gene contains 6 exons and 5 introns, spanning approximately 100 kb on chromosome 2p13 (Derynck et al., 1985) . We have identi®ed a novel exon within intron 5 and an alternative splice acceptor site in the middle of exon 6. Alternative splicing at these sites produces two variant TGF-a mRNAs, in addition to wt TGF-a. Unlike wt TGF-a, both variant TGF-a mRNAs encode polypeptides lacking carboxyl-terminal valine residues. When overexpressed in CHO cells that do not express endogenous TGF-a, both variants were susceptible to calcium ionophore-induced cleavage. Serum also induced cleavage of both variants and wt alike, although not eciently. However, results obtained in the CHO cells may not necessarily re¯ect the properties of these variants in other cell types. Therefore, we are currently exploring the proteolytic processing of wt and variant TGF-a in normal HKc and HKc/HPV16 in our in vitro model of multi-step carcinogenesis (Pirisi et al., 1987 (Pirisi et al., , 1988 as well as in human epithelial cells derived from a variety of human tumors. The only signi®cant dierence in the primary structure among the three forms of TGF-a precursors is that the two carboxyl-terminal valine residues in wt TGF-a are replaced by ®ve (GCRLY) or four (ATLG) amino acids in TGF-a VaI and variant II, respectively (Figure 1c ).
The only additional dierence is a micro-heterogeneity splicing between intron 2 and exon 3 that we observed in the variants. This small dierence, which results in the loss of an alanine residue near the N-terminus, was previously described in rat TGF-a where it was without functional signi®cance (Blasband et al., 1990) . The carboxyl-termini may have distinct biological functions in the three TGF-a forms. The clonal growth assays demonstrate an increased ability of TGF-a variants to support growth of CHO cells under reduced serum conditions, and CHO cells expressing TGF-a VaII are morphologically dierent from their controls and form foci in monolayer cultures. CHO cells, which do not express endogenous TGF-a, have been useful for the initial characterization of these variants, and for a ®rst assessment of their processing and functions. However, both processing and biological functions of these variants remain to be elucidated in normal as well as transformed human epithelial cells, which express and utilize TGF-a.
A bidirectional function was proposed for the TGFa precursor almost a decade ago (Pfeer and Ulrich, 1985; Massague and Pandiella, 1993) . Recent ®ndings in other transmembrane growth factor families support this possibility. For example, it was demonstrated that the transmembrane ligands for the EPH-family receptor Nuk had a signaling function (Holland et al., 1996) . A Prosite database search of the cytoplasmic tail of wt TGF-a and TGF-a variants revealed a candidate site for prenylation in TGF-a VaI. Prenylation is the covalent addition of either farnesyl (15-carbon), or more commonly, geranylgeranyl (20-carbon) isoprenoids via thioester linkages to cysteine residues at or near the carboxyl-terminus of proteins (Casey and Seabra, 1996; Zhang and Casey, 1996) . The attached lipid functions either as a mediator of membrane association or as a determinant for speci®c protein-protein interactions (Casey and Seabra, 1996; Zhang and Casey, 1996) . Immunoprecipitation using an antibody raised against the carboxyl-terminal peptide of wt TGF-a identi®ed the association of a kinase protein p86 with the cytoplasmic tail of the TGF-a precursor, in CHO cells overexpressing wt TGF-a (Shum et al., 1996) . This association required palmitoylation of cysteines 153 and 154. Mutation analysis of the carboxyl-terminus by Shum et al. (1994) demonstrated that alterations in the carboxyl-terminus may change palmitoylation of cysteines 153 and 154 and therefore alter protein-protein interactions. The possible prenylation site in TGF-a VaI may determine novel protein-protein interactions through the attached lipid, and therefore mediate interactions/functions speci®c for this TGF-a variant.
Materials and methods

Cell culture
CHO K1 cells (ATCC CCL-61) were grown in Ham's F12 medium (Gibco) with 10% fetal bovine serum (FBS) (Sigma) free of antibiotics. CHO K1 cells stably transfected with the expression vector pcDNA3.1 (Invitrogen) only, or with pcDNA3.1 containing TGF-a cDNA sequences were maintained in the same medium in the presence of 300 mg/ml G418 (Calbiochem or Gibco). HKc, HKc/HPV16 (Pirisi et al., 1988) , W12 clone 20861, and clone 20863 (Jeon et al., Figure 6 Clonal growth assays of CHO cells expressing wt and variant TGF-a precursors. Assays were performed as described in the text, and the total colony area in each dish was measured by a computerized image analysis system. The total colony area in the presence of 1 or 0.1% serum was normalized against that in the presence of 10% serum. The error bars represent standard deviations
Alternatively spliced forms of TGF-a X Xu et al 1995) were cultured in complete serum-free MCDB153-LB medium (CM) (Gibco) (Pirisi et al., 1988) . HKc/GFI were maintained in CM lacking EGF and BPE (Pirisi et al., 1988) . HKc/DR were maintained in CM supplemented with 5% FBS and 1 mM calcium chloride. HeLa (HPV18-positive cervical adenocarcinoma cells) were maintained in MEM medium supplemented with 10% FBS. A431 (vulvar squamous carcinoma cells), SiHa (derived from an HPV16-positive CIN lesion), CaSki (HPV16-positive cervical carcinoma) cells, and T24 bladder transitional carcinoma cells were grown in Dulbecco's modi®ed Eagle's medium (DMEM) supplemented with 10% FBS. QGH (HPV16-related cervical carcinoma), HT3 (cervical carcinoma), ME180 (HPV78-related cervical carcinoma), SW754 (vulva squamous carcinoma), QGU (HPV16-related cervical carcinoma), C33A (cervical carcinoma), SaOs (osteogenic sarcoma), MS751 (cervical epidermoid carcinoma), Detroit562 (pharynx carcinoma), SW837 (rectum adenocarcinoma), MG63 (osteosarcoma), DU145 (prostate carcinoma), MDA468 (breast adenocarcinoma) were maintained in DMEM/F12 (1 : 1) containing 10% FBS. SCC-9 (tongue squamous carcinoma) cells were maintained in the same medium plus 4 mg/ml hydrocortisone. NCI-HT69 (lung small cell carcinoma) cells were maintained in RPMI medium containing 10% FBS. All cells were incubated in a 378C incubator, in an atmosphere of 5% CO 2 and 95% air.
Cloning of TGF-a variants
TRI REAGENT (Molecular Research) was used to isolate total RNA from the cultured cells. One microgram of total RNA from HKc/GFI was used as template for RT ± PCR. RT ± PCR was performed using the Access RT ± PCR system (Promega). For ampli®cation of TGF-a fragments¯anking the possible alternative splice sites at the 3' UTR, we used combinations of the forward primer RPAS: 5'-CTT GGT GGT GGT CTC CAT CG-3' (nucleotides 337 ± 356 of the TGF-a cDNA, GenBank accession number X70340) with the following reverse primers: SPA1: 5'-AGC TAG GTG CAC TTA AGA G-3' (nucleotides 2035 ± 2053); SPA2: 5'-CAG GCT CCA TAA GAG TAT TGG-3' (nucleotides 3075 ± 3095), or SPA3: 5'-GCG TCT TAT ATT GCT CAC TAC TC-3' (nucleotides 3980 ± 4002) to explore the use of the possible splice acceptor sites at nucleotides 1751 or 1820, 2918, and 3830, respectively. RT ± PCR reactions were conducted according to the following protocol: 60 min at 488C for reverse transcription, 2 min at 948C for inactivation of AMV reverse transcriptase, followed by 40 cycles of PCR, (30 s at 948C, 1 min at 558C, and 3 min at 728C). Products from the combination of RPAS and SPA1 whose sizes were about 500 nucleotides were eluted from agarose gel using the GenClean kit (Bio101), and used as template for nested PCR by the combination of forward primer CYS: 5'-GCT TGC TGC CAC TCA GAA AC-3' (nucleotides 485 ± 504) and SPA1. The nested PCR program included an initial denaturation at 948C for 2 min, followed by 30 cycles, each with 30 s at 948C, 1 min at 558C, and 1 min at 728C. The resulting PCR product of about 300 nucleotides was cloned into pGEMT-easy vector (Promega) and sequenced by T7 Sequenase (Amersham).
For ampli®cation of cDNAs containing the full-length coding sequence of the alternatively spliced TGF-a mRNAs, combinations of forward primer 5' UTRS: 5'-TGC TGC CCG CCC GCC CGT AAA ATG-3' (nucleotides 11 ± 34) or 5' ENDS: 5'-GTA AAA TGG TCC CCT CGG CTG-3' (nucleotides 27 ± 47) and SPA1 were used for RT ± PCR to isolate the cDNA, and for nested PCR to further con®rm the identity of the RT ± PCR product. The same RT ± PCR program and nested PCR program described above were used, except that the elongation time at 688C was 2 min instead of 3 min and that the elongation time at 728C was 2 min instead of 1 min, respectively. The resulting nested-PCR product of about 800 nucleotides was cloned into the pGEMT-easy vector, and ®ve individual clones were isolated and sequenced. Sequencing revealed two TGF-a variants, whose sizes were 782 and 811 bp. The corresponding plasmids were named pGEM-VaI and pGEM-VaII, respectively.
The DyNAzyme EXT PCR validation kit (Finnzymes) was used for ampli®cation of a genomic fragment spanning from exon 4 to exon 6A of the TGF-a gene, on the template of human genomic DNA (Promega), with the combination of RPAS and E6A primers. The PCR program consisted of an initial denaturation at 948C for 2 min followed by ten cycles of three-temperature PCR (948C for 10 s, 608C for 30 s, 708C for 10 min), and then another 15 cycles of three-temperature PCR with a 20-s increment of the elongation period at each cycle. The PCR product was cloned into pGEM-T Easy vector (Promega) and sequenced using nested primers and the T7 sequenase (Amersham).
Ribonuclease protection assay
PCR was employed to amplify cDNA fragments speci®c to TGF-a variant I, variant II, and wt TGF-a. By using TGF-a VaI or VaII as template, the combination of the forward primer VAS: 5'-CAT CAC ATG TGT GCT GAT ACA C-3' (nucleotides 376 ± 397) and the reverse primer VAA: 5'-CCT AGG GAT GAG CTA TCC AC-3' (nucleotides 1908 AC-3' (nucleotides ± 1927 produced 307-and 339-nucleotide fragments, respectively. On phagemid TGF-a DNA template (ATCC), the combination of primers E6S: 5'-GAG TTT GGC CAG GTG GAC TG-3' (nucleotides 529 ± 548) and E6A: 5'-CTA TGG CTC GTG GCT AAT GTT C-3' (nucleotides 1564 ± 1585) generated a 1057-nucleotide fragment. All three fragments were individually cloned into the pGEMT-Easy vector and sequenced. The resulting plasmids were designated as pGEM-RPAVaI, pGEM-RPAVaII, and pGEM-RPAWT respectively. SacII (Promega) was used to linearize pGEM-RPAVaI and pGEMRPAVaII for probe synthesis. Antisense ribo-probes were transcribed in vitro with SP6 RNA polymerase (Promega). The sizes of the transcription products were 398 nucleotides and 430 nucleotides, with predicted protected fragments of 307 nucleotides and 339 nucleotides for TGF a variants I and II, respectively. We used AlwNI (New England Biolab) to linearize pGEM-RPAWT for probe synthesis, and SP6 RNA polymerase to produce the antisense riboprobe in vitro. The size of the probe was 355 nucleotides with a predicted protected fragment of 273 nucleotides (nucleotides 1310 ± 1585 in the TGF-a sequence). We also used SP6 RNA polymerase to transcribe a cyclophilin template (Ambion) and produce a riboprobe that served as an internal control for RNA quantitation. This riboprobe was 195 nucleotides in size, with a protected fragment of 103 nucleotides. Twenty to twenty-®ve micrograms of total RNA were used for RPA (HybSpeed RPA kit, Ambion), according to the manufacturer's instructions. Gels were exposed to a Phosphorimager and the radioactivity in each band was analysed by the ImageQuant software (Molecular Dynamics).
Plasmid construction and cell transfections
PCR-based site-directed mutagenesis was used to insert the HA (YPYDVPDYA) epitope into the N-terminus of mature TGFa (between amino acids 4 and 5 of the mature TGF-a moiety), to engineer a perfect Kozak sequence (Kozak, 1984 (Kozak, , 1997 and to eliminate the 3' UTR (Figure 3) . Primers TAKOZS containing an EcoRI cut site (underlined in the sequence below) and the Kozak sequence and TAHATAGA were used to insert a Kozak sequence and HA epitope into TGF-a cDNAs, respectively. Human wt proTGF-a cDNA containing the complete protein-coding region was generated by PCR using phagemid TGF-a cDNA (ATCC) as template and 5' ENDS and RPAA as primers, the resulting plasmid was designated as pGEM-WT. On the templates of pGEM-WT, pGEM-VaI, and pGEM-VaII, the ®rst PCR used primers TAKOZS and TAHATAGA; puri®ed PCR products were then used as forward primers in the second PCR with the vector reverse primer SP6 (pGEM-WT), or VAVIA (pGEM-VaI and pGEM-VaII) containing an EcoRI site (underlined in the sequence below). The ®nal PCR products were cut with EcoRI and inserted into the eukaryotic expression vector pcDNA3.1/ Neo (Invitrogen). The resulting plasmids were designated as pcDNA-HAWT, pcDNA-HAVaI, and pcDNA-HAVaII respectively. The sequences of these primers were as follows: RPAA, 5'-TTG ATC TGC CAC AGT CCA CC-3' (nucleotides 540 ± 549); TAKOZS, 5'-GTG TGG TGG AAT TCG CCA CCA TGG TCC CCT CGG CTG G-3'; TAHATAGA, 5'-CTG GGC AGT CAT TAA AAG CGT AGT CTG GGA CGT CGT ATG GGT AAT GGG ACA CCA CTG CTG-3'; VAEIA, 5'-TAT CTG CAG AAT TCT TAA TAA AGC CGG CAT C-3'. The authenticity of cloned sequences was con®rmed by sequencing.
The WT and variant TGF-a expression vectors were introduced into CHO cells by calcium phosphate transfection. Multiple G418-resistant clones were isolated, and the expression levels of the HA-tagged proteins were determined by Western blot analysis with the anti-HA antibody.
Analysis of HA-tagged proTGF-a processing in CHO cells
Cells were cultured until 80 ± 90% con¯uent and serumstarved for 1 h prior to the addition of the inducers in serumfree medium. The calcium ionophore A23187 (Sigma) was dissolved in DMSO and added to the culture medium at a ®nal concentration of 1 mM. The ®nal DMSO concentration in the medium was not greater than 0.1%. Controls received DMSO alone. After starvation, medium was replaced by fresh serum-free medium with 1 mM calcium ionophore A23187 or by fresh medium with 10% FBS. Cell lysates were collected at the following times, 0, 30, 60, 90, 120, 150, and 180 min. Cell lysates from control cells in serum-free medium with or without 0.1% DMSO were collected as well.
Cells were washed in cold PBS twice and lysed in lysis buer (1% Triton X-100, 1% sodium deoxycholate, 20 mM Tris, pH 7.5, 150 mM NaCl, 10 mM EDTA, 5 mg/ml aprotinin, and 1 mM PMSF). Lysates were cleared by centrifugation, and protein concentrations were determined using the DC protein assay kit (Bio-Rad). Lysates were separated by 12% SDS ± PAGE. Gels were then soaked for 15 min in transfer buer (25 mM Tris base, 192 mM glycine, 20% methanol), and proteins were transferred onto prewetted nitrocellulose membrane (pore size: 0.2 nm, Bio-Rad). Blots were blocked in 2% non-fat milk in Dulbecco's phosphatebuered saline (Gibco) containing 0.1% Tween-20 (BioRad) (PBS-T) at 48C overnight, rinsed in PBS-T for 5 min and incubated with rat anti-HA antibody (0.2 mg/mL, Boehringer Mannheim) for 2 h at room temperature. Blots were quickly rinsed in PBS-T twice, and washed in PBS-T for 4610 min periods, then incubated with biotinylated goat anti-rat IgG (1 : 5000) (Jackson ImmunoResearch Laboratories) in PBS-T containing 2% milk for an additional 60 min. Blots were extensively washed, and incubated with streptavidin-HRP (Amersham) in PBS-T containing 1% casein for another 60 min. After extensive washing, blots were incubated in SuperSignal substrate or Blaze (Pierce) for 5 min before exposing them to X-ray ®lm to detect chemiluminescence.
Clonal growth assay
Clonal growth assays were performed as previously described for normal HKc and HKc/HPV16 (Zyzak et al., 1994) , with some modi®cations. Brie¯y, CHO cells transfected with an empty vector or expressing wt or variant TGF-a precursors were plated on 60-mm tissue culture dishes (1000 cells per dish). Triplicate dishes were fed 8 ml of F12 medium containing 10, 1, or 0.1% serum 24 h after plating for 5 days. Cells were ®xed with methanol and stained with Giemsa. Colony area was measured by a computerized image analysis system. Abbreviations TGF-a, transforming growth factor a; proTGF-a, TGF-a precursor; VHL, von Hippel-Lindau; HKc, human keratinocytes; HPV16, human papillomavirus type 16; HKc/ HPV16, HKc immortalized by HPV16; HKc/GFI, growth factor-independent HKc/HPV16; HKc/DR, dierentiation resistant HKc/HPV16; UTR, untranslated region; CHO, Chinese hamster ovary; FBS, fetal bovine serum; RPA, ribonuclease protection assay; PBS, phosphate-buered saline; PMA, phorbol 12-myristate 13-acetate; DMSO, dimethylsulfoxide; PKC, protein kinase C; EGFR, epidermal growth factor receptor.
